Early progression of disease as a predictor of survival in chronic lymphocytic leukemia

Key points – Early progression of disease within 2 years of initial therapy independently predicts inferior survival in CLL. Early progression of disease is a robust clinical end point and a useful posttreatment risk stratification tool.